INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 423m ago
HOUSE PTR23m ago
SEC 13F22m ago
ROBINHOOD CHAIN22m ago
Public company

TSHATaysha Gene Therapies, Inc.

CIK 0001806310

EDGAR filingsOpen in network
Disclosed transactions18
Buys / sells0 / 6
Max Insider Score36
Connections5with evidence

TSHA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M$33K
19.0K sh
Apr 10, 2026Apr 13, 2026
traded Apr 10, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Lobbied forevidence
    AVIVA STRATEGIES (FKA MGB CONSULTING)LDA Q2Y 2026 second quarter · issues not listed · Aug 26, 2026
  • ← Insider ofevidence
    Alam KamranCHIEF FINANCIAL OFFICER · Jan 14, 2026
  • ← Insider ofevidence
    Nolan Sean P.Director, Chief Executive Officer · Jan 14, 2026
0
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M
—
19.0K sh
Apr 10, 2026
Apr 13, 2026
traded Apr 10, 2026
+3d
SEC FORM 4

Evidence

11
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale · 10b5-1 plan
SELL$892K
200.0K sh
Apr 10, 2026Apr 13, 2026
traded Apr 10, 2026
+3dSEC FORM 4

Evidence

36
AK
Alam KamranCHIEF FINANCIAL OFFICER
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$375K
79.0K sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC FORM 4

Evidence

32
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$423K
89.1K sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC FORM 4

Evidence

25
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$124K
26.9K sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC FORM 4

Evidence

25
AK
Alam KamranCHIEF FINANCIAL OFFICER
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$110K
23.8K sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC FORM 4

Evidence

11
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M—
111.3K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

7
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M—
88.7K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

0
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Grant or award · 10b5-1 plan
A—
274.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

17
NP
Nolan Sean P.Director, Chief Executive Officer
TSHATaysha Gene Therapies, Inc.
Grant or award
A—
1.01M sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

9
NP
Nolan Sean P.Director, Chief Executive Officer
TSHATaysha Gene Therapies, Inc.
Grant or award
A—
648.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

17
AK
Alam KamranCHIEF FINANCIAL OFFICER
TSHATaysha Gene Therapies, Inc.
Grant or award
A—
359.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

9
AK
Alam KamranCHIEF FINANCIAL OFFICER
TSHATaysha Gene Therapies, Inc.
Grant or award
A—
231.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

6
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M$78K
111.3K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

6
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M$152K
88.7K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale · 10b5-1 plan
SELL$942K
200.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

7
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Grant or award · 10b5-1 plan
A—
427.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Nagendran SukumarDirector, President and Head of R&D · Jan 14, 2026

    • Lobbying

    $20K reported · de-duplicated
    2026 Q2 $20K via firms2026 Q1 $0 via firms
    • AVIVA STRATEGIES (FKA MGB CONSULTING)—2026 Q1 · posted Aug 26, 2026 ·
    • AVIVA STRATEGIES (FKA MGB CONSULTING)$20K2026 Q2 · posted Aug 26, 2026 ·

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.